Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley A, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23. No abstract available.

2.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

3.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
4.

Does the benefit justify the risk?

Albertsen PC.

J Natl Cancer Inst. 2010 Jan 6;102(1):4-5. doi: 10.1093/jnci/djp427. Epub 2009 Dec 7. No abstract available.

PMID:
19996059
5.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-9. doi: 10.1111/bju.12732. Epub 2014 Jul 27.

6.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.

Eur Urol. 2012 Jun;61(6):1119-28. doi: 10.1016/j.eururo.2012.01.045. Epub 2012 Feb 1.

7.

Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.

J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792. Epub 2015 Mar 2.

PMID:
25732167
8.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
9.

Is hormone ablation still the right choice for advanced prostate cancer?

Fitzpatrick JM.

BJU Int. 2007 Jul;100 Suppl 2:36-9. Review. No abstract available.

10.

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

Eur Urol. 2013 Jul;64(1):159-66. doi: 10.1016/j.eururo.2012.04.035. Epub 2012 Apr 19.

11.

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

JAMA Oncol. 2016 Apr;2(4):500-7. doi: 10.1001/jamaoncol.2015.4917.

PMID:
26720632
12.

Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.

Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20.

PMID:
25990353
13.

Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer.

Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF.

Asian J Androl. 2015 May-Jun;17(3):493-6. doi: 10.4103/1008-682X.143313.

14.

[Androgen deprivation therapy and morbid obesity: do they share cardiovascular risk through metabolic syndrome?].

Cleffi S, Neto AS, Reis LO, Maia P, Fonseca F, Wroclawski ML, Neves M, Pompeo AC, Del Giglio A, Faria EF, Tobias-Machado M.

Actas Urol Esp. 2011 May;35(5):259-65. doi: 10.1016/j.acuro.2011.01.011. Epub 2011 Apr 2. Spanish.

PMID:
21459486
15.

Researchers probe consequences of androgen deprivation for prostate cancer.

Friedrich MJ.

JAMA. 2006 Nov 15;296(19):2305-6. No abstract available.

PMID:
17105787
16.

Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.

Saylor PJ, Keating NL, Freedland SJ, Smith MR.

Drugs. 2011 Feb 12;71(3):255-61. doi: 10.2165/11588930-000000000-00000. No abstract available.

17.

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.

Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Review.

18.

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.

Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. Review.

PMID:
23092636
19.

Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden.

Robinson D, Garmo H, Lindahl B, Van Hemelrijck M, Adolfsson J, Bratt O, Holmberg L, Stattin P.

Int J Cancer. 2012 Jan 15;130(2):478-87. doi: 10.1002/ijc.26022. Epub 2011 May 2.

20.

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19.

Supplemental Content

Support Center